Clinical trials
First-line Treatment clinical trials
Below are recruiting first-line treatment clinical trials, each written for real people, not researchers. We’re tracking 423 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05260671RecruitingPhase 2
Penpulimab plus cetuximab for advanced head and neck cancer
This trial studies penpulimab (an immune medicine) combined with cetuximab (an antibody drug) for recurrent or metastatic squamous cell head and neck cancer that cannot be treated with surgery or radiation. It aims to shrink tumors and improve survival in people whose tumor shows a specific immune marker (PD-L1).
Changchun, JilinAges 18–80 - NCT05271916RecruitingPhase 1/Phase 2
New targeted drugs for advanced lung cancer with EGFR L858R
This study tests whether taking dacomitinib plus anlotinib as a first treatment can shrink or control advanced lung cancer that has the EGFR L858R mutation. It may help people who have not had any standard drug treatment yet, especially if their brain metastases are stable.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05302284RecruitingPhase 3
Testing RC48-ADC plus toripalimab for first-time urothelial cancer
This trial tests whether RC48-ADC combined with toripalimab works better as the first treatment for urothelial cancer that cannot be removed by surgery or has spread. It may help shrink tumors and improve outcomes in people whose cancer has the right HER2 and other eligibility features.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05321758Recruiting
Stool transplant as first treatment for kids with Crohn’s
This study tests whether transferring healthy gut bacteria from stool into the colon can work as a first treatment for children newly diagnosed with mild-to-moderate Crohn’s disease. It may help reduce inflammation and improve symptoms, and it requires regular colonoscopy to monitor progress.
Wuhan, HubeiAges 2–16 - NCT05345158Recruiting
Robotic surgery first for early-stage seminoma testicular cancer
This trial studies whether a robotic operation (removing cancerous lymph nodes in the back of the belly) is a good first treatment for certain early-stage testicular seminoma cases. It aims to cure cancer while avoiding or delaying other treatments, and uses follow-up plans to check results.
Toronto, OntarioAges 18 years+ - NCT05379803RecruitingPhase 2
High-dose furmonertinib for lung cancer with brain metastases
This trial tests a high-dose targeted pill, furmonertinib, in people with EGFR-mutated non-small cell lung cancer that has spread to the brain. It aims to better control both the lung cancer and the brain metastases by targeting a specific gene change.
Changsha, HunanAges 18 years+ - NCT05511623RecruitingPhase 2
Tislelizumab with chemoradiotherapy for stage IIIC2 cervical cancer
This trial tests whether adding tislelizumab to standard chemotherapy and radiation works better as first treatment for stage IIIC2 cervical cancer. It aims to improve how well the cancer responds and controls the disease.
Nanning, GuangxiAges 18–70 - NCT05594927RecruitingPhase 3
Test icaritin vs huachansu for advanced liver cancer with poor health
This Phase 3 trial compares two medicines—icaritin soft capsules versus huachansu tablets—as first treatment for unresectable hepatocellular carcinoma (HCC) that has “poor prognosis” blood test markers. It aims to see which option works better and is safer for people who can’t use standard first-line treatments or don’t want them.
Nanchang, JiangxiAges 18 years+ - NCT05598528Recruiting
Study why some lung cancers don’t respond to EGFR pills
This study looks at why certain EGFR-positive advanced lung cancers resist third-generation EGFR tablet treatment given as the first treatment. Your body samples and scan results help researchers understand the resistance, which may guide better future care.
Changsha, HunanAges 18 years+ - NCT05737303RecruitingPhase 3
First-line chemotherapy comparison for advanced ovarian cancer
This Phase 3 trial compares two chemotherapy drug approaches (nab-paclitaxel vs another taxane drug) as the first treatment for advanced ovarian, fallopian tube, or peritoneal cancer. It aims to find which option works better and is tolerated better in people with stage III–IV disease.
Guangzhou, GuangdongAges 18–75 - NCT05744687RecruitingPhase 2/Phase 3
Letrozole plus SPH4336 versus letrozole alone for breast cancer
This study tests whether adding SPH4336 to letrozole works better than letrozole plus a placebo for treating hormone-receptor–positive, HER2-negative breast cancer in people starting first-line treatment. It may help slow cancer growth more effectively if the added drug is beneficial.
Fuzhou, FujianAges 18–75 - NCT05751018RecruitingPhase 2
Pyrotinib for first treatment of HER2-mutated lung cancer
This Phase 2 trial studies pyrotinib as a first (initial) anti-cancer treatment for advanced lung cancer that has specific HER2 changes. It aims to shrink tumors and control the cancer, especially in people whose test results show HER2 insertion mutation, point mutation, or amplification.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05760378RecruitingPhase 3
Famitinib plus immunotherapy for advanced triple-negative breast cancer
This Phase 3 trial tests a combination of famitinib (a cancer drug that targets blood vessel growth) with immunotherapy drugs in people with newly diagnosed advanced triple-negative breast cancer that has spread or cannot be fully removed. It aims to improve how long patients live and how well the cancer responds.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05765084RecruitingPhase 1/Phase 2
Atezolizumab plus WT1 vaccine with chemo for pleural mesothelioma
This trial studies a treatment plan that combines an immune drug (atezolizumab) and a personalized cancer vaccine (WT1/DC) with standard first-line chemotherapy for epithelioid malignant pleural mesothelioma that cannot be removed with surgery. It aims to improve control of the cancer by helping the immune system work alongside chemotherapy.
Edegem, AntwerpAges 18 years+ - NCT05806060RecruitingPhase 3
Targeted first treatment for a rare TNBC subtype with spread
This Phase 3 trial tests a more precise treatment strategy for a specific rare type of triple-negative breast cancer (TNBC) called the BLIS subtype. It’s for people whose cancer has spread or cannot be fully removed and who have not had chemo or targeted therapy for metastatic TNBC yet.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05838066RecruitingPhase 3
KN026 plus HB1801 for HER2-positive advanced breast cancer
This Phase 3 study tests whether taking KN026 with HB1801 as first treatment works better and is safe for people with HER2-positive breast cancer that has come back or spread. It may help by improving tumor response and delaying progression compared with the study’s treatment plan.
Beijing, chaoyangAges 18 years+ - NCT05854849RecruitingPhase 3
Testing three-drug therapy versus cisplatin for recurrent NPC
This trial studies whether gemcitabine plus camrelizumab plus apatinib works better than cisplatin alone for people with recurrent or metastatic non-keratinizing nasopharyngeal cancer. It’s meant for people who haven’t had prior whole-body (systemic) treatment for the returning/spreading cancer.
Guangzhou, GuangdongAges 18–75 - NCT05859750RecruitingPhase 2
AK104 plus chemotherapy for advanced pancreatic cancer
This trial tests AK104 (an antibody medicine) given with standard chemotherapy as the first treatment for advanced pancreatic ductal cancer. It aims to see whether this combination works better and is safe for people with cancer that has spread or is advanced.
Beijing, Beijing MunicipalityAges 18–75 - NCT05877573Recruiting
Toripalimab with chemo-radiation before surgery for rectal cancer
This trial studies whether adding toripalimab (an immunotherapy drug) to standard chemo-radiation before surgery can improve outcomes for people with higher-risk, locally advanced rectal cancer. It is meant for cancers that are mismatch-repair “MSS/pMMR,” and it checks safety plus effectiveness as a first treatment.
Guangzhou, GuangdongAges 18–75 - NCT05899608RecruitingPhase 3
Testing ivonescimab as first treatment for metastatic lung cancer
This Phase 3 trial tests ivonescimab as a first-line treatment for metastatic non-small cell lung cancer (NSCLC). It may help people by improving how well the cancer responds, especially in tumors with PD-L1 activity, but you must meet specific medical and testing requirements.
Phoenix, ArizonaAges 18 years+ - NCT05918094RecruitingPhase 3
Testing new chemo plan plus immunotherapy for stomach cancer
This phase 3 study compares two versions of a first-time treatment for HER2-negative advanced stomach or gastroesophageal cancer, both including immunotherapy (sintilimab). It looks for a safer or more effective way to slow cancer growth or improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT05926700RecruitingPhase 2
Testing cadonilimab plus anlotinib for advanced soft tissue sarcoma
This Phase 2 study tests two medicines (cadonilimab and anlotinib) in people with advanced soft tissue sarcoma whose cancer grew after standard first treatment. It aims to see whether the combination can shrink tumors and improve safety.
HangzhouAges 18 years+ - NCT05928039RecruitingPhase 4
Choosing the best first biologic for Crohn’s in the ileum
This Phase 4 trial tests which type of biologic medicine works best as the first treatment for people with moderate-to-severe Crohn’s that mainly affects the ileum. It may help you and your care team choose a more effective first option, based on which strategy leads to better control of symptoms and intestinal inflammation.
Calgary, AlbertaAges 18 years+ - NCT05958875RecruitingPhase 4
Six-week medicine switch for schizophrenia after first treatment failure
This trial tests whether a more intensive medication approach for schizophrenia (or related conditions) helps people who didn’t improve on their first tried medicine. Participants will usually switch medicines and be compared against “treatment as usual.”
InnsbruckAges 18–70
Hear when a new First-line Treatment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for first-line treatment?
- Yes. Clin2 currently lists 423 recruiting first-line treatment studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a first-line treatment trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a first-line treatment trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.